AMRI Appoints New President, India Operations and New Director of Project Management – Pharmaceutical Services
News Oct 17, 2011
Reporting to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing at AMRI, Mr. Maddala brings more than 20 years of operations, business development, and senior leadership experience in the manufacturing of APIs and intermediates, custom synthesis, and formulations in branded and generics markets. Most recently, he served as vice president, Contract Research and Manufacturing Services (CRAMS) and New Generics for Shasun Pharmaceuticals Limited, and was responsible for Shasun’s contract research and manufacturing business, including all vertical CRAMs businesses and new API generic efforts. Prior to that, Mr. Maddala held several roles of increasing responsibility at such firms as Piramal India Limited, Glenmark Pharmaceuticals, Medicorp/Matrix Labs, Torrent Pharmaceuticals, SOL and Lupin Laboratories.
Mr. Maddala earned a Master of Science degree in Applied Chemistry from the University of Baroda, India and a Bachelor of Science degree in Chemistry from Osmania University in Hyderabad, India.
AMRI is also pleased to announce that Dr. Rajesh Shenoy, managing director, AMRI India will be relocating back to the United States to assume the position of director, project management-pharmaceutical services, continuing to report to Dr. Hagen. Dr. Shenoy will have full leadership responsibilities for AMRI’s global project management activities throughout the pharmaceutical services sector, including small scale, large scale, GMP activities, formulations development and manufacturing, and sterile fill and finish. Dr. Shenoy joined AMRI in 1998. He earned a Ph.D. in organic chemistry at the University of Akron and conducted postdoctoral research at Kent State University. Prior to his assignment in India, Dr. Shenoy held positions of increasing responsibility in AMRI’s discovery and development services operations.
“We are pleased to welcome Mr. Maddala to the AMRI leadership team and believe he is the right person to take AMRI’s chemical manufacturing business in India to the next level, including the capability to eventually manufacture multiple products in India to U.S. FDA standards.” Dr. Hagen continued, “Dr. Shenoy’s return to the United States caps a six-year assignment in which he established, built, and oversaw AMRI’s Hyderabad laboratory operations, eventually assuming leadership for all of our country operations in India, including our manufacturing activities in Aurangabad. We appreciate his continued contributions to AMRI and wish them both great successes in their new roles.”
Comments | 0 ADD COMMENT
Orphan Drugs and Rare Diseases Global Congress 2017 USA
Sep 12 - Sep 14, 2017